-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Atopic Neonatal Barrier Dysfunction (BABY) study analyzed 450 infants (300 term and 150 preterm newborns) to examine whether the skin barrier and immune biomarkers could predict the onset and severity
The study found that full-term and premature infants with elevated levels of TARC (thymus and activation of modulating chemokines) at two months of age were more than twice as likely to develop eczema at age two years as normal infants
The researchers used tape to collect skin cells painlessly and noninvasively from the skin between the back of 0-3-day and 2-month-old full-term infants and the shoulder blades of 2-month-old premature infants
Dr Anne-Sophie Haring, lead author and co-researcher from Bispebjerg Hospital at the University of Copenhagen, commented: "To our knowledge, this is the first study
"This research will help us investigate and create future prevention strategies for children with elevated TARC levels to help stop the development of this debilitating common disease, which is an exciting prospect
Eczema affects up to 20% of the pediatric population, and diagnoses continue to rise
"This test is painless and easy to perform and can help us identify skin changes before eczema occurs, especially for the most severe forms of
Two other biomarkers— interleukin (IL)-8 and IL-18—have also been associated
